Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy for treating hypercholesterolemia

a hypercholesterolemia and conjugate technology, applied in the field of conjugate therapy for treating hypercholesterolemia, can solve the problems of unsatisfactory polymer efficacy, complex manufacturing process, and unpalatable polymer, and achieve the effect of reducing serum cholesterol and reducing serum cholesterol

Inactive Publication Date: 2010-10-21
GENZYME CORP
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention relates to methods and pharmaceutical compositions for treating hypercholesterolemia and atherosclerosis. The methods involve administering a combination of an unsubstituted polydiallylamine polymer and a cholesterol-lowering agent such as fibrates, nicotinic acid, or other compounds. The pharmaceutical compositions contain the same combination of compounds. The unsubstituted polydiallylamine polymer is characterized by the absence of certain monomers and the optionally crosslinked state. The technical effects of the invention include reducing serum cholesterol and treating hypercholesterolemia and atherosclerosis.

Problems solved by technology

It has been long recognized that this polymer is unpalatable, gritty, and constipating.
In some cases, these polymers have had disappointing efficacy and require complex processes for their manufacture.
The side effects of niacin are well-known and usually limit usage.
For example, high doses cause pruritis and flushing.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy for treating hypercholesterolemia
  • Combination therapy for treating hypercholesterolemia
  • Combination therapy for treating hypercholesterolemia

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Poly(Diallylammonium Chloride)

[0056]Concentrated hydrochloric acid (507.0 g; 37%) was charged to a 5 L, 3-neck round bottomed flask and agitated with a mechanical stirrer. The flask was cooled to <5° C. with an ice bath. Diallylamine (635.0 ml) was added dropwise to the stirring hydrochloric acid over a three hour period using an addition funnel capped with a pierced rubber septum.

[0057]The stirring solution temperature was maintained at <10° C. After the addition was completed, the ice bath was removed and the mixture was allowed to warm to room temperature. Concentrated hydrochloric acid (7.3 g) was added to the solution. Water (368.7 g) was added to the solution and it was allowed to sit overnight.

[0058]The stirring solution was purged with nitrogen gas for 30 minutes at room temperature. 2,2′-Azobis[2-amidinopropane]dihydrochloride (6.87 g) was added as 34.4 g of a 20% aqueous solution. The solution was heated to 60°-80° C. for six and one-half hours. 2,2′-Azobis[...

example 2

Synthesis of Polydiallylamine

[0060]A solution of 39.3 g of an aqueous solution (68 wt %) of diallylammonium hydrochloride, 5.3 g of an aqueous solution (73 wt %) of triallylamine hydrochloride and 0.9 g of 2,2′-azobis(2-amidinopropane)dihydrochloride was bubbled with a slow stream of nitrogen for 30 minutes. While stirring, this reaction mixture was added to a solution of 7 g of polyvinylacetate in 300 mL of toluene. The resulting mixture was stirred at room temperature for 45 minutes under nitrogen atmosphere. While stirring, the temperature of the reaction mixture was raised to 60 C and was held at this temperature for 24 hours. The reaction mixture was allowed to cool to room temperature and the polymer particles were collected by filtration. While in the funnel, the filtered particles were successively washed with 300 mL of toluene and 500 mL of methanol. The polymer particles were suspended in 500 mL of methanol, stirred for 50 minutes, and filtered.

[0061]Subsequently, the part...

example 3

Cross-Linked Polydiallylamine

[0062]The polymer solution of Example 1 was crosslinked at 30 mole % as follows:

[0063]Epichlorohydrin (31.61 mL) was added to 900.0 g of the neutralized polymer solution in a glass beaker, agitated with a magnetic stirrer and covered with polyvinyl film. The gel was allowed to cure for 22 hours. The solid gel was then ground using a grinder. The ground polymer was washed in a static bed manner using a large plastic Buchner funnel lined with filter paper. A second piece of filter paper, perforated with holes, was placed on top of the polymer cake to prevent disturbing the cake when adding wash water. Fresh deionized H2O (14 L) was added to the top of the cake and drained under vacuum. The washed polymer was then transferred to glass drying trays and dried in a 60° C. forced air oven for several days. The final dry weight was 176.2 g.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount.The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.

Description

RELATED APPLICATIONS[0001]This application is a Continuation of U.S. application Ser. No. 10 / 025,184, filed Dec. 19, 2001, which is a Continuation of U.S. application Ser. No. 09 / 311,103, filed on May 13, 1999, now U.S. Pat. No. 6,264,938, which is a Continuation-in-Part of U.S. application Ser. No. 08 / 964,536, filed on Nov. 5, 1997, now U.S. Pat. No. 6,083,497. The entire teachings of the above applications are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]Reabsorption of bile acids from the intestine conserves lipoprotein cholesterol in the bloodstream. Conversely, blood cholesterol levels can be diminished by reducing reabsorption of bile acids.[0003]One method of reducing the amount of bile acids that are reabsorbed and, thus, reducing serum cholesterol is the oral administration of compounds that sequester the bile acids and cannot themselves be absorbed. The sequestered bile acids are excreted.[0004]Compounds which have been suggested for bile acid sequestr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/785A61P3/06A61K31/787A61P7/02A61P9/10
CPCY10S514/824A61K31/785A61P1/16A61P3/00A61P3/06A61P43/00A61P7/02A61P9/10
Inventor HUVAL, CHAD CORIHOLMES-FARLEY, STEPHEN RANDALLPETERSEN, JOHN S.DHAL, PRADEEP K.
Owner GENZYME CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com